Roth Capital Reiterates $32 PT on Stemline Therapeutics (STML) as Breakthrough Therapy Granted

August 23, 2016 9:27 AM EDT
Get Alerts STML Hot Sheet
Price: $12.07 -2.27%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade STML Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Roth Capital analyst Joseph Pantginis reiterated a Buy rating and $32 price target on Stemline Therapeutics (NASDAQ: STML) after the company announced the FDA has granted Breakthrough Therapy Designation to SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Pantginis notes, presently, no standards of care exist in both the front-line and relapsed/refractory settings for BPDCN.

Pantginis commented, "We believe that this is a major step forward for STML and SL-401 and look toward further updates later this year, including ASH."

For an analyst ratings summary and ratings history on Stemline Therapeutics click here. For more ratings news on Stemline Therapeutics click here.

Shares of Stemline Therapeutics closed at $7.40 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Momentum Movers, Trader Talk

Related Entities

Roth Capital

Add Your Comment